MANGALAM vs ZIMLAB: Stock Comparison

Mangalam Drugs And Organics Limited vs Zim Laboratories Limited

Live data: 22 July 2026, 2:57 PM IST • Source: NSE and company filings

Zim Laboratories Limited is the larger company by market capitalisation. Zim Laboratories Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Mangalam Drugs And Organics Limited and Zim Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MANGALAM is more favourable on 2 of 11 scored metrics and ZIMLAB on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ZIMLAB is the larger company
₹656 Cr vs ₹43 Cr
EPS
ZIMLAB has higher earnings per share
₹1.94 vs ₹-28.05
Dividend Yield
ZIMLAB has a higher dividend yield
0.02% vs 0%
Revenue Growth (TTM YoY)
ZIMLAB has faster revenue growth
-3.36% vs -7.5%
EPS Growth (TTM YoY)
MANGALAM has faster EPS growth
0% vs -47.01%
Qtr Sales Growth
MANGALAM has stronger quarterly sales growth
-7.54% vs -12.3%
Qtr Profit Growth
ZIMLAB has stronger quarterly profit growth
-308% vs -22,467%
ROE
ZIMLAB has a higher ROE
1.97% vs -35.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMANGALAMZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMANGALAMZIMLAB
Live Price₹27.08₹104.91
Day Change-0.66%0.25%
Volume25,35681,241
52-Week High₹95₹121.47
52-Week Low₹22.8₹59.31
Distance from 52W High-71.49%-13.63%

Valuation

MetricMANGALAMZIMLAB
Market Cap₹43 Cr₹656 Cr
P/E Ratio112.39x
P/B Ratio2.21x
EPS₹-28.05₹1.94
Book Value₹65.12₹51.77
Dividend Yield0%0.02%

Growth

MetricMANGALAMZIMLAB
Revenue Growth (TTM YoY)-7.5%-3.36%
EPS Growth (TTM YoY)0%-47.01%
Qtr Sales Growth-7.54%-12.3%
Qtr Profit Growth-22,467%-308%

Profitability & Leverage

MetricMANGALAMZIMLAB
ROE-35.2%1.97%
ROCE-14.3%8.16%
Net Margin-19.13%1.56%
Operating Margin-6.42%5.72%
Debt to Equity1.02x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricMANGALAMZIMLAB
Promoter Holding35.65%30.36% 0.01 pp
FII Holding0.11% 0.21 pp0.03% 0.03 pp
DII Holding0%1.33% 1.26 pp
Public Holding64.24% 0.22 pp68.28% 1.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Mangalam Drugs And Organics Limited and Zim Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.